Saffati G, Kassab J, Orozco Rendon D, Hinojosa-Gonzalez DE, Kronstedt S, Lipshultz LI, Khera M

Disclosures: Kali Zhou: Gilead Sciences Inc: Grant/Research Support, Christopher Wong: Nothing to Disclose, Aaron Ahearn: Nothing to Disclose, Jeffrey Kahn: Orphalon: Single Advisory Board meeting 11/2023, Malinckrodt: Attended speaker's training session, never spoke, Orphalon: Single advisory board meeting, 2023, Norah Terrault: Elseiver: Royalties or patent beneficiary, GSK: Grant/Research Support, Eiger Pharmaceuticals: Grant/Research Support, Helio Health: Grant/Research Support, Durect Corp: Grant/Research Support, ImmunoCore: Grant/Research Support, HBV Foundation: Board member, AASLD: Executive role 1207 ASSESSING THE PREVALENCE OF CARDIOMETABOLIC RISK FACTORS IN PATIENTS REFERRED TO A STEATOTIC LIVER DISEASE CLINIC Yousef Almahanna 1 Ahmed Almohsen 1 Yi Nong Song 1 Amani Bajunayd 1 Jeemin Kim 1 Adrienne Abaya 1 Rokhsana Mortuza 1 Mohammad Qasim Khan 1 Juan Pablo Arab 1 , 1 University of Western Ontario Background: The metabolic syndrome is a known risk factor for development of hepatic steatosis

2425 New Holland Pike, Lancaster, PA 17601, USA Authorship & conflict of interest Contributions: AS Prakasha Gowda conceived, designed, performed the experiments and wrote manuscript
This mindfulness practice teaches your brain that your dizziness is not dangerous to you